Solasia Pharma K.K Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Solasia Pharma K.K wird ein Gewinn- und Umsatzwachstum von 64.7% bzw. 36% pro Jahr prognostiziert, während der Gewinn pro Aktie um 66.4% pro Jahr wachsen soll.

Wichtige Informationen

64.7%

Wachstumsrate der Gewinne

66.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	20.2%
Wachstumsrate der Einnahmen	36.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

TSE:4597 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,829	96	142	203	1
12/31/2025	1,717	-926	-937	-753	1
12/31/2024	1,657	-538	-544	-501	1
3/31/2024	408	-1,181	-746	-746	N/A
12/31/2023	617	-1,112	-359	-359	N/A
9/30/2023	1,209	-1,267	-1,240	-1,240	N/A
6/30/2023	1,432	-1,738	-1,839	-1,441	N/A
3/31/2023	1,199	-2,174	-1,681	-1,282	N/A
12/31/2022	1,092	-2,548	-2,477	-2,074	N/A
9/30/2022	761	-2,416	-1,980	-1,520	N/A
6/30/2022	470	-2,331	-2,380	-2,214	N/A
3/31/2022	581	-2,437	-2,558	-2,392	N/A
12/31/2021	559	-2,478	-2,636	-2,473	N/A
9/30/2021	450	-4,301	-2,711	-2,595	N/A
6/30/2021	492	-4,249	-2,478	-2,360	N/A
3/31/2021	389	-4,252	-2,857	-2,688	N/A
12/31/2020	454	-4,127	-2,960	-2,789	N/A
9/30/2020	1,306	-2,132	-1,911	-1,699	N/A
6/30/2020	1,420	-2,046	-1,788	-1,676	N/A
3/31/2020	1,405	-1,838	-1,045	-980	N/A
12/31/2019	1,310	-1,867	-1,560	-828	N/A
9/30/2019	499	-2,561	-2,607	-1,846	N/A
6/30/2019	364	-2,599	-2,751	-1,969	N/A
3/31/2019	372	-2,662	-3,250	-2,381	N/A
12/31/2018	318	-2,422	-2,580	-2,323	N/A
9/30/2018	111	-2,129	-2,536	-2,238	N/A
6/30/2018	489	-1,378	-1,965	-1,440	N/A
3/31/2018	414	-1,086	-1,685	-1,169	N/A
12/31/2017	410	-1,007	N/A	-911	N/A
9/30/2017	709	-493	N/A	N/A	N/A
12/31/2016	501	-762	N/A	-464	N/A
12/31/2015	229	-917	N/A	N/A	N/A
12/31/2014	11	-677	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4597 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (0.2%).

Ertrag vs. Markt: 4597 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: 4597 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: 4597Die Einnahmen des Unternehmens (36% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (4.1% pro Jahr).

Hohe Wachstumseinnahmen: 4597Die Einnahmen des Unternehmens (36% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4597 in 3 Jahren voraussichtlich hoch sein wird

Solasia Pharma K.K Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 66%

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Recent updates

First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023)

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 66%

New major risk - Financial position

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Solasia Pharma K.K. to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001).

Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021)

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Launch of Darvias in Japan

Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021)

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare

First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021)

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. to Report Q3, 2022 Results on Nov 11, 2022

Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020)

Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021

New 90-day high: JP¥158

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Solasia Pharma K.K. to Report Fiscal Year 2020 Results on Feb 16, 2021

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2020

New 90-day low: JP¥123

Solasia Pharma K.K. announced that it expects to receive ¥13.44 million in funding from Macquarie Group Limited

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken